DNX-2401 + Pembrolizumab for Recurrent Glioblastoma
Study 2401BT-002P (CAPTIVE) is a Phase 2 trial being conducted in collaboration with Merck to evaluate the efficacy and safety of DNX-2401 in combination with pembrolizumab (KEYTRUDA), Merck’s anti-PD-1 therapy. Adult subjects diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.
DNX-2401 for Pediatric Patients with Newly Diagnosed Pontine Glioma
Study D24-DIPG is a Phase 1 trial to evaluate the safety and efficacy of DNX-2401 in pediatric patients. Patients who are less than 18 years old with newly diagnosed diffuse intrinsic pontine glioma may be eligible.
DNX-2440 for Recurrent Glioblastoma
Study D2440GBM1 is a Phase 1 trial being conducted at Clinica Universidad de Navarra (Spain) to evaluate the safety and efficacy of DNX-2440. Adult subjects with diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.
Expanded Access/Compassionate Use:
At this time, DNAtrix does not offer expanded access or compassionate use programs for investigational agents under development. We evaluate the need on a continuous basis.
Virus artwork by Luke Jerram